Comprehensive Notes on Gene Therapy

Gene Therapy

  • Gene therapy is a treatment or prevention method for diseases that involves:
    • Replacing a faulty gene.
    • Inactivating a malfunctioning gene.
    • Introducing a new or modified gene.

Types of Gene Therapy

  • Somatic Gene Therapy
    • Targets non-reproductive cells.
    • Effects are not heritable (i.e., not passed on to future generations).
    • Most current gene therapy treatments fall under this category.
  • Germline Gene Therapy (not approved for use in humans)
    • Targets sperm or egg cells.
    • Changes are heritable, meaning they can be passed on to future generations.
    • Raises significant ethical and safety concerns.
  • In vivo Gene Therapy
    • Therapeutic genetic material is delivered directly into a patient's tissues or bloodstream.
    • This is done using vectors without removing cells from the body.
  • Ex vivo Gene Therapy
    • Patient-derived cells are genetically modified outside the body.
    • These genetically modified cells are then reintroduced back into the patient.

Delivery Methods (Vectors)

  • Viral Vectors
    • Delivery Efficiency: High
    • Duration of Expression: Long-term, especially with integrating vectors
    • Examples: Adenovirus, AAV (adeno-associated virus), and lentivirus
    • Immune Response: Often triggers an immune response
  • Non-Viral Methods
    • Delivery Efficiency: Generally low to moderate
    • Duration of Expression: Mostly transient
    • Examples: Plasmids, liposomes, and nanoparticles
    • Immune Response: Minimal immune reaction

Case Study: Spinal Muscular Atrophy (SMA) Type 1

  • Overview:
    • Definition: A severe neuromuscular disorder.
    • Pathophysiology: Loss of the SMN1 gene causes motor neuron degeneration, leading to muscle weakness and wasting. SMA Type 1 is the leading genetic cause of infant death.
    • Onset: Typically occurs before 6 months of age. Without treatment, it has high mortality by age 2.
  • Genetic Cause:
    • Patients usually have a homozygous deletion or mutation in the SMN1 gene.
    • SMN2 is a backup gene that produces only a small amount of functional SMN protein due to alternative splicing.
    • Prevalence: Occurs in approximately 1 in 6,0006,000 to 1in10,0001 in 10,000 live births.
    • Carrier frequency: 1 in 40 to 1 in 60
  • Mechanism of SMA Type 1:
    • SMN1 deficiency leads to splicing defects.
    • This results in motor neuron degeneration, causing muscle weakness and wasting.
  • SMN1 Gene Details:
    • Location: Chromosome 5q13.2
    • Inheritance: Autosomal recessive

Gene Therapy for Spinal Muscular Atrophy Type 1 (SMA1)

  • Why AAV (Adeno-Associated Virus)?
    • AAV crosses the blood-brain barrier, making it effective for targeting the central nervous system (CNS).
    • AAV can target motor neurons.
  • Mechanism:
    • An AAV-based viral vector is used to deliver a functional copy of the SMN1 gene to motor neurons.
    • Administered via a single-dose intravenous injection.
  • Key Features:
    • One-time systemic administration is sufficient.
    • The SMN1 gene is delivered episomally (non-integrating).
    • Episomal delivery reduces the risk of insertional mutagenesis.